Analysis of the PetMeds Board
PetMed's board seems to have been assembled with shareholder value, strategic capabilities, and operational expertise in mind.
Peter Batushansky brings the most direct industry experience. He founded and built Allivet. Allivet was one of PetMed's largest competitors before it sold the business. He understands customer acquisition, prescription fulfillment, veterinary relationships, margins, and industry consolidation. He knows what strategic buyers look for in a pet pharmacy business. If PetMeds is sold, his experience will be highly valuable.
James LaCamp joined the board in October 2025 and serves as Audit Chair. At age 42, he is still an active operating executive, currently serving as Skydio's CFO. Previously, he was CFO of Flock Safety, SVP of Finance at Coupa Software, and an audit partner at Deloitte. He holds an accounting degree from Santa Clara University, an MBA from Wharton, and is a CPA. He also serves as a director and Audit Committee Chair at Performant Healthcare.
LaCamp was not recruited for pet industry expertise. Instead, he brings deep experience in financial analysis, capital allocation, M&A, corporate strategy, and shareholder value creation. He will be an influential director in evaluating a turnaround, a restructuring, a strategic review, or a sale.
Justin Mennen adds technology and digital retail expertise. Since PetMeds competes against much larger online players such as Chewy and Amazon. His background is relevant. His skill set is valuable if the board believes improvements in technology, customer retention, marketing efficiency, and online conversion can drive a turnaround
Leah Solivan is the founder of TaskRabbit. She brings together entrepreneurship and transactional experience. She built and sold a successful company to IKEA. She understands both value creation and value realization. Her background suggests an objective approach. If a turnaround offers the best return? She would likely support. If a sale creates more value, she can evaluate it.
Leslie Campbell has served on the board since 2018. She became Chair in January 2024. And accepted the role as Interim CEO in August 2025 after the departures of both the CEO and CFO. Her background includes senior leadership roles at Oracle and Dell. And has expertise in finance, technology, governance, and board oversight.
Campbell is not known as an activist investor or turnaround specialist. But several factors make her more open to strategic alternatives than prior management. She purchased 60,000 shares in the open market in late 2024. Her career has focused on governance and shareholder oversight rather than empire building. This could make her more open to a transaction.
The leadership change can create an opportunity for the board to reassess strategy. The company still possesses valuable assets, a recognized brand, pharmacy licenses, and a large customer base with recurring autoship revenue. These characteristics could make it attractive to strategic buyers.
The board previously declined acquisition offers. And Campbell's priorities as Interim CEO are likely stabilizing operations and recruiting permanent executive leadership. The most probable outcome is that the board first attempts to improve performance. And reviewing all strategic alternatives.
Conclusion
The board is strong for a company of PetMeds' size. Batushansky provides industry expertise. LaCamp contributes financial and strategic discipline. Mennen adds technology and digital commerce experience. And Solivan brings entrepreneurship and M&A knowledge. This is combined with Campbell's background in governance. The board appears built to evaluate a wide range of options.
